Patient-Centered Research Acceleration

Has led a nationwide advocacy campaign for over 10 years to ban paraquat, a pesticide linked to increased Parkinson's risk. Advocated for a bipartisan Farm Bill amendment in 2026 and is actively working on paraquat legislation in 12 states including New York, Pennsylvania, and Minnesota.

Conducts the Parkinson’s Progression Markers Initiative (PPMI), a long-term study collecting biological, genetic, and clinical data from over 4,200 in-person and nearly 50,000 online participants to understand early stages of Parkinson’s and identify biomarkers. Includes recruitment of individuals with REM sleep behavior disorder and use of wearable sensors and DaT scans.

Has funded over $2.5 billion in Parkinson's research programs, awarded 108 grants totaling $62.4 million in 2025 alone, and supported therapeutic development including stem cell engineering and drug development for LRRK2 and GBA1 targets. The foundation has transformed genetic discoveries like LRRK2 into druggable targets and advanced biomarker tools such as the alpha-synuclein seed amplification assay.

Operates Fox Trial Finder, a tool that matches people with Parkinson's to recruiting clinical studies, facilitating over 15,000 referrals since 2020. Also provides access to virtual clinical trials remotely and supports screening and participation in longitudinal studies like PPMI and NeuLark.

Organizes the Run/Walk Series and Tour de Fox Cycling Series to engage communities in fundraising for Parkinson's research, contributing to over $30 million raised since 1994, including $2.4 million in 2025.

Deploys staff and supports participation in the World Parkinson Congress, including hosting policy discussions, contributing lived expertise, moderating research sessions, and supporting event planning.

Provides U.S. and U.K. participants with access to their research results—including smell test, alpha-synuclein spinal fluid test, motor signs test, and DaT scan—through the myPPMI portal.

Played a key role in building bipartisan support leading to the establishment of the National Parkinson’s Project, submitted public comments to its Advisory Council, and organized the 2026 Parkinson’s Policy Forum in Washington, D.C., where 300 advocates met with over 240 congressional offices.

Engages thousands of Team Fox members globally in fundraising activities for Parkinson's research.

Featured Michael J. Fox in a three-episode arc on Apple TV's "Shrinking" to portray a character living with Parkinson's, using his return to acting to demonstrate continued engagement in passions and inspire the Parkinson’s community.

Funds and manages a grant program that provides financial assistance for assistive equipment, technology, and therapy treatments for individuals with KAT6A and KAT6B syndromes.

Provides financial support for scientific research into disease mechanisms, treatments, and biomarkers for KAT6A and KAT6B syndromes, including funding studies at UCLA, Spain, and eight new research projects in 2025. Also funded the first clinical description of KAT6A syndrome (2015) and the largest cohort study to date (2019).

Organizes an annual KATwalk event that raises funds and awareness for KAT6-related causes; the 2024 event raised $200,000 USD.

Runs a specialized clinical program providing comprehensive, coordinated care for patients diagnosed with KAT6A or KAT6B syndromes, integrating medical, developmental, and therapeutic services.

Runs a longitudinal patient registry launched in 2019 to collect and analyze health, development, and clinical data on individuals with KAT6A and KAT6B syndromes, supporting therapeutics development and care improvement. Includes biobanking of biospecimens and family-reported survey data on symptoms, medications, and care.

Hosts a semi-annual virtual symposium series that convenes researchers to share findings, collaborate, and advance scientific understanding of KAT6A and KAT6B syndromes.

Offers global support services including education, conference calls, and assistance with patient registration through NORD (National Organization for Rare Disorders). Includes ongoing volunteer support to help families access therapies and assistive equipment.

Provides access to Antidote Match, a tool that matches individuals with PBC to recruiting clinical trials, helping patients participate in research and treatment development.